North America Pharmacokinetics Services Market Forecast to 2031

At 8.0% CAGR, North America Pharmacokinetics Services Market is Projected to be Worth US$ 692.77 Million by 2031, says Business Market Insights

According to Business Market Insights’ research, the North America pharmacokinetics services market was valued at US$ 375.36 million in 2023 and is expected to reach US$ 692.77 million by 2031, registering a CAGR of 8.0% from 2023 to 2031. Rising prevalence of chronic and infectious diseases and expanding range of application of pharmacokinetic studies are among the critical factors attributed to drive the North America pharmacokinetics services market growth.

The growing prevalence of chronic diseases such as diabetes, cancer, and autoimmune diseases has been a prime enabler of drug development efforts across the world. According to the World Health Organization’s (WHO) 2024 data, ~422 million in the world suffer from diabetes, and these cases are mostly found in middle and low-income countries, causing approximately 1.5 million deaths every year. Pharmaceutical companies are at the forefront of developing drugs to treat various diseases. Pharmacokinetic studies are essential for understanding how these drugs behave in a patient’s body by analyzing the process of absorption, distribution, metabolization, and elimination (ADME) within the human body. The absorption of a drug into systemic circulation affects the speed and concentration at which a drug may reach the site of action, e.g., plasma. Drug distribution pattern throughout the body varies based on its biochemical properties and body physiology. Metabolism involves the processing of the drug by the body into subsequent compounds. This step is instrumental in converting the drug into water-soluble substances to render them suitable for renal clearance. Metabolism is also important for the conversion of prodrugs, such as codeine, into active metabolites. Excretion of drugs from the body is mainly governed by kidneys; however, in several cases, drugs may be excreted via the lungs, skin, or gastrointestinal tract. ADME dynamics define the bioavailability of drugs in the body, and the maintenance doses of drugs are calculated based on their clearance times (desired plasma concentration divided by bioavailability). Understanding of clearance allows practitioners to calculate appropriate dosing rates.

Pharmacokinetic studies focus on optimizing drug dose regimens in study subjects to understand the efficacy and safety of a drug. These studies are essential for ensuring the safety of drugs that are developed for long-term treatments, which helps evaluate the suitability and stability of drug formulations in chronic disease management. Hence, the rising burden of chronic and infectious diseases underlines the importance of pharmacokinetic studies to develop safe and effective personalized treatments.

On the contrary, limited reach of pharmacokinetics service providers in emerging countries hamper the growth of North America pharmacokinetics services market.

Based on drug type, the North America pharmacokinetics services market is segmented small molecule, large molecule, and vaccines. The small molecule segment held 50.4% market share in 2023, amassing US$ 189.03 million. It is projected to garner US$ 363.90 million by 2031 to register 8.5% CAGR during 2023-2031.

In terms of service type, the North America pharmacokinetics services market is categorized into pre-clinical ADME and human studies, PK/PD analysis and reporting, dosing simulations, risk analysis, and others. The pre-clinical ADME and human studies segment held 35.3% share of North America pharmacokinetics services market in 2023, amassing US$ 132.34 million. It is anticipated to garner US$ 269.59 million by 2031 to expand at 9.3% CAGR during 2023-2031.

By therapeutic application, the North America pharmacokinetics services market is segmented into oncology, infectious diseases, neurological disorders, autoimmune diseases, gynecological disorders, cardiovascular diseases, respiratory disorders, and others. The oncology segment held 22.2% market share in 2023, amassing US$ 83.20 million. It is projected to garner US$ 170.90 million by 2031 to register 9.4% CAGR during 2023-2031.

By end user, the North America pharmacokinetics services market is segmented into pharmaceutical and biotechnology companies, contract research organization, and others. The contract research organization segment held 43.3% market share in 2023, amassing US$ 162.42 million. It is projected to garner US$ 316.30 million by 2031 to register 8.7% CAGR during 2023-2031.

By country, the North America pharmacokinetics services market is segmented into the US, Canada, and Mexico. Our regional analysis states that the US captured 80.5% share of North America pharmacokinetics services market in 2023. It was assessed at US$ 302.22 million in 2023 and is likely to hit US$ 566.34 million by 2031, registering a CAGR of 8.2% during 2023-2031.

Key players operating in the North America pharmacokinetics services market are Charles River Laboratories International Inc; Eurofins Scientific SE; Evotec SE; Certara Inc.; Parexel International Corp; Thermo Fisher Scientific Inc.; Allucent; PACIFIC BIOLABS; and SGS SA; among others.

o Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the North America pharmacokinetics services market.
o Highlights key business priorities in order to assist companies to realign their business strategies.
o The key findings and recommendations highlight crucial progressive industry trends in the North America pharmacokinetics services market, thereby allowing players across the value chain to develop effective long-term strategies.
o Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
o Scrutinize in-depth North America market trends and outlook coupled with the factors driving the North America pharmacokinetics services market, as well as those hindering it.
o Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing, and distribution.

TABLE OF CONTENTS

1. Introduction
1.1 The Research Team Research Report Guidance
1.2 Market Segmentation
2. Executive Summary
2.1 Key Insights
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. North America Pharmacokinetics Services Market Landscape
4.1 PEST Analysis
5. North America Pharmacokinetics Services Market – Key Market Dynamics
5.1 Market Drivers
5.1.1 Rising Prevalence of Chronic and Infectious Diseases
5.1.2 Expanding Range of Application of Pharmacokinetic Studies
5.1.3 Outsourcing of Pharmacokinetics Services to CROs
5.2 Market Restraints
5.2.1 Limited Reach of Pharmacokinetics Service Providers in Emerging Countries
5.3 Market Opportunities
5.3.1 Increasing Adoption of In-Vivo and In-Vitro Models for Understanding Variability in Pharmacokinetics
5.4 Future Trend
5.4.1 Increasing Adoption of Big Data Analytics in Pharmacokinetics Services
5.5 Impact of Drivers and Restraints:
6. Pharmacokinetics Services Market – North America Analysis
6.1 North America Pharmacokinetics Services Market Revenue (US$ Million), 2021-2031
7. North America Pharmacokinetics Services Market Analysis – by Drug Type
7.1 Overview
7.2 Small Molecule
7.2.1 Overview
7.2.2 Small Molecule: North America Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
7.3 Large Molecule
7.3.1 Overview
7.3.2 Large Molecule: North America Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
7.4 Vaccines
7.4.1 Overview
7.4.2 Vaccines: North America Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
8. North America Pharmacokinetics Services Market Analysis – by Service Type
8.1 Overview
8.2 Pre-Clinical ADME and Human Studies
8.2.1 Overview
8.2.2 Pre-Clinical ADME and Human Studies: North America Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
8.3 PK/PD Analysis and Reporting
8.3.1 Overview
8.3.2 PK/PD Analysis and Reporting: North America Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
8.4 Dosing Simulations
8.4.1 Overview
8.4.2 Dosing Simulations: North America Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
8.5 Risk Analysis
8.5.1 Overview
8.5.2 Risk Analysis: North America Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
8.6 Others
8.6.1 Overview
8.6.2 Others: North America Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
9. North America Pharmacokinetics Services Market Analysis – by Therapeutic Application
9.1 Oncology
9.1.1 Overview
9.1.2 Oncology: North America Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
9.2 Infectious Diseases
9.2.1 Overview
9.2.2 Infectious Diseases: North America Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
9.3 Neurological Disorders
9.3.1 Overview
9.3.2 Neurological Disorders: North America Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
9.4 Autoimmune Diseases
9.4.1 Overview
9.4.2 Autoimmune Diseases: North America Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
9.5 Gynecological Disorders
9.5.1 Overview
9.5.2 Gynecological Disorders: North America Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
9.6 Cardiovascular Diseases
9.6.1 Overview
9.6.2 Cardiovascular Diseases: North America Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
9.7 Respiratory Disorders
9.7.1 Overview
9.7.2 Respiratory Disorders: North America Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
9.8 Others
9.8.1 Overview
9.8.2 Others: North America Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
10. North America Pharmacokinetics Services Market Analysis – by End User
10.1 Pharmaceutical and Biotechnology Companies
10.1.1 Overview
10.1.2 Pharmaceutical and Biotechnology Companies: North America Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
10.2 Contract Research Organization
10.2.1 Overview
10.2.2 Contract Research Organization: North America Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
10.3 Others
10.3.1 Overview
10.3.2 Others: North America Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
11. North America Pharmacokinetics Services Market – Country Analysis
11.1 North America
11.1.1 North America Pharmacokinetics Services Market Breakdown, by Key Countries, 2023 and 2031 (%)
11.1.1.1 United States: North America Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
11.1.1.1.1 Overview
11.1.1.1.2 United States: North America Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
11.1.1.1.3 United States: North America Pharmacokinetics Services Market Breakdown, by Drug Type
11.1.1.1.4 United States: North America Pharmacokinetics Services Market Breakdown, by Service Type
11.1.1.1.5 United States: North America Pharmacokinetics Services Market Breakdown, by Therapeutic Application
11.1.1.1.6 United States: North America Pharmacokinetics Services Market Breakdown, by End User
11.1.1.2 Canada: North America Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
11.1.1.2.1 Overview
11.1.1.2.2 Canada: North America Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
11.1.1.2.3 Canada: North America Pharmacokinetics Services Market Breakdown, by Drug Type
11.1.1.2.4 Canada: North America Pharmacokinetics Services Market Breakdown, by Service Type
11.1.1.2.5 Canada: North America Pharmacokinetics Services Market Breakdown, by Therapeutic Application
11.1.1.2.6 Canada: North America Pharmacokinetics Services Market Breakdown, by End User
11.1.1.3 Mexico: North America Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
11.1.1.3.1 Overview
11.1.1.3.2 Mexico: North America Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
11.1.1.3.3 Mexico: North America Pharmacokinetics Services Market Breakdown, by Drug Type
11.1.1.3.4 Mexico: North America Pharmacokinetics Services Market Breakdown, by Service Type
11.1.1.3.5 Mexico: North America Pharmacokinetics Services Market Breakdown, by Therapeutic Application
11.1.1.3.6 Mexico: North America Pharmacokinetics Services Market Breakdown, by End User
12. Company Profile
12.1 Charles River Laboratories International Inc
12.1.1 Key Facts
12.1.2 Business Description
12.1.3 Products and Services
12.1.4 Financial Overview
12.1.5 SWOT Analysis
12.1.6 Key Developments
12.2 Eurofins Scientific SE
12.2.1 Key Facts
12.2.2 Business Description
12.2.3 Products and Services
12.2.4 Financial Overview
12.2.5 SWOT Analysis
12.2.6 Key Developments
12.3 Evotec SE
12.3.1 Key Facts
12.3.2 Business Description
12.3.3 Products and Services
12.3.4 Financial Overview
12.3.5 SWOT Analysis
12.3.6 Key Developments
12.4 Certara Inc.
12.4.1 Key Facts
12.4.2 Business Description
12.4.3 Products and Services
12.4.4 Financial Overview
12.4.5 SWOT Analysis
12.5 Parexel International Corp
12.5.1 Key Facts
12.5.2 Business Description
12.5.3 Products and Services
12.5.4 Financial Overview
12.5.5 SWOT Analysis
12.5.6 Key Developments
12.6 Thermo Fisher Scientific Inc.
12.6.1 Key Facts
12.6.2 Business Description
12.6.3 Products and Services
12.6.4 Financial Overview
12.6.5 SWOT Analysis
12.6.6 Key Developments
12.7 Allucent
12.7.1 Key Facts
12.7.2 Business Description
12.7.3 Products and Services
12.7.4 Financial Overview
12.7.5 SWOT Analysis
12.7.6 Key Developments
12.8 PACIFIC BIOLABS
12.8.1 Key Facts
12.8.2 Business Description
12.8.3 Products and Services
12.8.4 Financial Overview
12.8.5 SWOT Analysis
12.8.6 Key Developments
12.9 SGS SA
12.9.1 Key Facts
12.9.2 Business Description
12.9.3 Products and Services
12.9.4 Financial Overview
12.9.5 SWOT Analysis
12.9.6 Key Developments
13. Appendix
13.1 About The Research Team
13.2 Glossary of Terms for Pharmacokinetic Services Market

LIST OF TABLES

Table 1. North America Pharmacokinetics Services Market Segmentation
Table 2. United States: North America Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million) – by Drug Type
Table 3. United States: North America Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million) – by Service Type
Table 4. United States: North America Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million) – by Therapeutic Application
Table 5. United States: North America Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million) – by End User
Table 6. Canada: North America Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million) – by Drug Type
Table 7. Canada: North America Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million) – by Service Type
Table 8. Canada: North America Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million) – by Therapeutic Application
Table 9. Canada: North America Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million) – by End User
Table 10. Mexico: North America Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million) – by Drug Type
Table 11. Mexico: North America Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million) – by Service Type
Table 12. Mexico: North America Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million) – by Therapeutic Application
Table 13. Mexico: North America Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million) – by End User
Table 14. Glossary of Terms

LIST OF FIGURES

Figure 1. North America Pharmacokinetics Services Market Segmentation, by Country
Figure 2. PEST Analysis
Figure 3. North America Pharmacokinetics Services Market – Key Market Dynamics
Figure 4. Impact Analysis of Drivers and Restraints
Figure 5. North America Pharmacokinetics Services Market Revenue (US$ Million), 2021-2031
Figure 6. North America Pharmacokinetics Services Market Share (%) – by Drug Type (2023 and 2031)
Figure 7. Small Molecule: North America Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
Figure 8. Large Molecule: North America Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
Figure 9. Vaccines: North America Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
Figure 10. North America Pharmacokinetics Services Market Share (%) – by Service Type (2023 and 2031)
Figure 11. Pre-Clinical ADME and Human Studies: North America Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
Figure 12. PK/PD Analysis and Reporting: North America Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
Figure 13. Dosing Simulations: North America Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
Figure 14. Risk Analysis: North America Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
Figure 15. Others: North America Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
Figure 16. North America Pharmacokinetics Services Market Share (%) – by Therapeutic Application (2023 and 2031)
Figure 17. Oncology: North America Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
Figure 18. Infectious Diseases: North America Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
Figure 19. Neurological Disorders: North America Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
Figure 20. Autoimmune Diseases: North America Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
Figure 21. Gynecological Disorders: North America Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
Figure 22. Cardiovascular Diseases: North America Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
Figure 23. Respiratory Disorders: North America Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
Figure 24. Others: North America Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
Figure 25. North America Pharmacokinetics Services Market Share (%) – by End User (2023 and 2031)
Figure 26. Pharmaceutical and Biotechnology Companies: North America Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
Figure 27. Contract Research Organization: North America Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
Figure 28. Others: North America Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
Figure 29. North America Pharmacokinetics Services Market by Key Countries – Revenue (2023) (US$ Million)
Figure 30. North America Pharmacokinetics Services Market Breakdown, by Key Countries, 2023 and 2031 (%)
Figure 31. United States: North America Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
Figure 32. Canada: North America Pharmacokinetics Services Market – Revenue and Forecast to 2031(US$ Million)
Figure 33. Mexico: North America Pharmacokinetics Services Market – Revenue and Forecast to 2031(US$ Million)